Stayble provides update on partnership activities
February 2025Stayble Therapeutics AB (“Stayble” or “the Company”) today provides an update on the ongoing work to establish partnerships for the pain treatment STA363. The Company is encouraged by the strong interest shown by both mid-sized and large pharmaceutical companies. The Board and management assess that there are good opportunities to enter into a partnership agreement based on the available Phase 1b results.
The Company’s goal is to find a licensee or partner with the right expertise and financial resources to drive the continued clinical development, commercialization, and launch of STA363. Intensive work is ongoing in collaboration with our transaction advisor. Their experience, expertise, and network provide the Company with opportunities to identify the right partner to further develop STA363. Currently, the Company is engaged in discussions with several potential partners, both in non-confidential initial talks and more in-depth confidential discussions. The need for new, safe, and effective treatment options for patients suffering from pain caused by herniated discs is substantial.
Andreas Gerward, CEO of Stayble Therapeutics, comments:
“We feel strong momentum, with the significant interest from multiple pharmaceutical companies confirming the great potential of STA363. We view the ongoing discussions positively and are hopeful about the possibility of executing a deal or a strategic collaboration with a relevant counterpart during 2025.”
For more information
Andreas Gerward, CEO of Stayble Therapeutics AB
Mail: andreas.gerward@stayble.se
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for lumbar disc herniation (LDH). Stayble’s vision is to offer patients a simple and effective treatment that targets the underlying cause of the patient’s chronic pain and provides lasting pain relief and increased physical function. The treatment is aimed at patients who are not helped by physical therapy and painkillers and is a single injection that is expected to last a lifetime and requires minimal rehabilitation. After convincing data from previous pre-clinical and clinical studies (phase 1b and 2b) in degenerative disc disease, which show a volume reduction of the discs, the Company has successfully completed a phase 1b study for the treatment of herniated discs.
The company’s Certified Adviser is Svensk Kapitalmarknadsgranskning AB.
